Imatinib tackles lymphomavia the PDGFRβ+ pericyte

Abstract

In this issue of Blood, Ruan et al demonstrate that the tyrosine kinase inhibitor (TKI), imatinib, can cause regression of human lymphomas in vivo; interestingly, this occurs via antiangiogenesis mediated by disruption of the platelet-derived growth factor receptor-b positive (PDGFRβ+) pericyte.